Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study

By afschroeder • June 5, 2025

Emu B, Kumar PN, Mills A, Berhe M, Cash BR, Kuo KL, Anstett K. Ibalizumab plus an optimized background regimen in treatment-experienced patients infected with multidrug resistant HIV-1: A phase 3, multicenter, expanded access study. J Acquir Immune Defic Syndr. 2025 Jun 4. doi: 10.1097/QAI.0000000000003699. Epub ahead of print. PMID: 40465394.

Tags: Humanized IgG4 monoclonal antibody, Ibalizumab, Infectious Diseases, Multidrug-resistant human immunodeficiency virus type 1, Optimized background regimen, Publications, Viral entry inhibitor

HIV Drug Resistance to Dolutegravir Among Adults Investigated for Antiretroviral Treatment Failure in Malawi: A 2023 National Cross-Sectional Survey

Kalata NL, Bello G, Pals S, Kabaghe AN, Mkungudza J, Bighignoli B, Panja L, Bilaal W, Kusakale G, Chitenje M, Luhanga M, Zeh C, Kampira[...]

The Relationship Between HIV Preexposure Prophylaxis Use and Laboratory-Confirmed Bacterial Sexually Transmitted Infection Positivity Among a Diverse, Multi-City Cohort of Sexually Active Sexual and Gender Minorities in the United States

Yonko EA, Tian J, Aminzadeh K, Qian Y, Noori G, Plankey M, Friedman MR, Palella FJ, Jones DL, Wingood G, Sharma A, Dionne JA, Edmonds[...]

Description of T-Cell and Monocyte Populations in the Circulation of People with HIV Prior to AIDS-NHL Diagnosis

Martínez LE, Comin-Anduix B, Güemes-Aragon M, Ibarrondo J, Detels R, Mimiaga MJ, Epeldegui M. Description of T-Cell and Monocyte Populations in the Circulation of People[...]